{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T13:45:59Z","timestamp":1791726359236,"version":"4.3.4"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T00:00:00Z","timestamp":1728345600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T00:00:00Z","timestamp":1728345600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["2004356"],"award-info":[{"award-number":["2004356"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["2004356"],"award-info":[{"award-number":["2004356"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"crossref","award":["104797"],"award-info":[{"award-number":["104797"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"crossref","award":["104797"],"award-info":[{"award-number":["104797"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"crossref","award":["104797"],"award-info":[{"award-number":["104797"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"crossref","award":["104797"],"award-info":[{"award-number":["104797"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"crossref","award":["104797"],"award-info":[{"award-number":["104797"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    The Clinical and Laboratory Standards Institute (CLSI) M27 guidelines are the recommended and most commonly used protocols for broth microdilution antifungal susceptibility testing of yeasts. However, these guidelines are limited to the use of 96-well assay plates, limiting assay capacity. With the increased risk of fungal resistance emerging in the community, it is important to have alternative protocols available, that offer higher throughput and can screen more than eight to ten potential antifungal compounds per plate. This study presents an optimised broth microdilution minimum inhibitory concentration (MIC) method for testing the susceptibility of yeasts in an efficient high throughput screening setup, with minimal growth variability and maximum reproducibility. We extend the M27 guidelines and optimise the conditions for 384-well plates. Validation of the assay was performed with ten clinically used antifungals (fluconazole, amphotericin B, 5-fluorocytosine, posaconazole, voriconazole, ketoconazole, itraconazole, caspofungin diacetate, anidulafungin and micafungin) against\n                    <jats:italic>Candida albicans<\/jats:italic>\n                    and\n                    <jats:italic>Cryptococcus neoformans<\/jats:italic>\n                    .\n                  <\/jats:p>","DOI":"10.1038\/s41598-024-74068-2","type":"journal-article","created":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T05:02:56Z","timestamp":1728363776000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Standardisation of high throughput microdilution antifungal susceptibility testing for Candida albicans and Cryptococcus neoformans"],"prefix":"10.1038","volume":"14","author":[{"given":"Holly E. E.","family":"Floyd","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela M.","family":"Kavanagh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabrielle J.","family":"Lowe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maite","family":"Amado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James A.","family":"Fraser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark A. T.","family":"Blaskovich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alysha G.","family":"Elliott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Zuegg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,8]]},"reference":[{"key":"74068_CR1","unstructured":"World Health Organization. WHO Fungal Priority Pathogens list to Guide Research, Development and Public Health Action (Geneva, 2022)."},{"key":"74068_CR2","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1007\/s11894-015-0436-2","volume":"17","author":"A Erdogan","year":"2015","unstructured":"Erdogan, A. & Rao, S. S. Small intestinal fungal overgrowth. Curr. Gastroenterol. Rep. 17, 16. https:\/\/doi.org\/10.1007\/s11894-015-0436-2 (2015).","journal-title":"Curr. Gastroenterol. Rep."},{"key":"74068_CR3","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1146\/annurev-micro-091014-104330","volume":"69","author":"CJ Nobile","year":"2015","unstructured":"Nobile, C. J. & Johnson, A. D. Candida albicans biofilms and human disease. Annu. Rev. Microbiol. 69, 71\u201392. https:\/\/doi.org\/10.1146\/annurev-micro-091014-104330 (2015).","journal-title":"Annu. Rev. Microbiol."},{"key":"74068_CR4","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1093\/bfgp\/elv035","volume":"15","author":"MZ Anderson","year":"2016","unstructured":"Anderson, M. Z. & Bennett, R. J. Budding off: bringing functional genomics to Candida albicans. Brief. Funct. Genomics. 15, 85\u201394. https:\/\/doi.org\/10.1093\/bfgp\/elv035 (2016).","journal-title":"Brief. Funct. Genomics"},{"key":"74068_CR5","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1086\/376536","volume":"188","author":"JR Naglik","year":"2003","unstructured":"Naglik, J. R. et al. Differential expression of Candida albicans secreted aspartyl proteinase and phospholipase B genes in humans correlates with active oral and vaginal infections. J. Infect. Dis. 188, 469\u2013479. https:\/\/doi.org\/10.1086\/376536 (2003).","journal-title":"J. Infect. Dis."},{"key":"74068_CR6","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1093\/cid\/civ933","volume":"62","author":"PG Pappas","year":"2016","unstructured":"Pappas, P. G. et al. Clinical practice Guideline for the management of Candidiasis: 2016 update by the Infectious Diseases Society of America. Clin. Infect. Diseases: Official Publication Infect. Dis. Soc. Am. 62, e1\u201350. https:\/\/doi.org\/10.1093\/cid\/civ933 (2016).","journal-title":"Clin. Infect. Diseases: Official Publication Infect. Dis. Soc. Am."},{"key":"74068_CR7","doi-asserted-by":"publisher","unstructured":"Spampinato, C. & Leonardi, D. Candida infections, causes, targets, and resistance mechanisms: traditional and alternative antifungal agents. Biomed. Res. Int. 2013 (204237). https:\/\/doi.org\/10.1155\/2013\/204237 (2013).","DOI":"10.1155\/2013\/204237"},{"key":"74068_CR8","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.fgb.2014.11.006","volume":"78","author":"JF Gibson","year":"2015","unstructured":"Gibson, J. F. & Johnston, S. A. Immunity to Cryptococcus neoformans and C. Gattii during cryptococcosis. Fungal Genet. Biol. 78, 76\u201386. https:\/\/doi.org\/10.1016\/j.fgb.2014.11.006 (2015).","journal-title":"Fungal Genet. Biol."},{"key":"74068_CR9","doi-asserted-by":"publisher","first-page":"565","DOI":"10.2217\/fmb.14.132","volume":"10","author":"S Rohatgi","year":"2015","unstructured":"Rohatgi, S. & Pirofski, L. A. Host immunity to Cryptococcus neoformans. Future Microbiol. 10, 565\u2013581. https:\/\/doi.org\/10.2217\/fmb.14.132 (2015).","journal-title":"Future Microbiol."},{"key":"74068_CR10","doi-asserted-by":"publisher","first-page":"a019760","DOI":"10.1101\/cshperspect.a019760","volume":"4","author":"KJ Kwon-Chung","year":"2014","unstructured":"Kwon-Chung, K. J. et al. Cryptococcus neoformans and Cryptococcus gattii, the etiologic agents of cryptococcosis. Cold Spring Harb Perspect. Med. 4, a019760. https:\/\/doi.org\/10.1101\/cshperspect.a019760 (2014).","journal-title":"Cold Spring Harb Perspect. Med."},{"key":"74068_CR11","doi-asserted-by":"publisher","first-page":"1748","DOI":"10.1016\/s1473-3099(22)00499-6","volume":"22","author":"R Rajasingham","year":"2022","unstructured":"Rajasingham, R. et al. The global burden of HIV-associated cryptococcal infection in adults in 2020: A modelling analysis. Lancet Infect. Dis. 22, 1748\u20131755. https:\/\/doi.org\/10.1016\/s1473-3099(22)00499-6 (2022).","journal-title":"Lancet Infect. Dis."},{"key":"74068_CR12","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1016\/s1473-3099(17)30243-8","volume":"17","author":"R Rajasingham","year":"2017","unstructured":"Rajasingham, R. et al. Global burden of disease of HIV-associated cryptococcal meningitis: An updated analysis. Lancet Infect. Dis. 17, 873\u2013881. https:\/\/doi.org\/10.1016\/s1473-3099(17)30243-8 (2017).","journal-title":"Lancet Infect. Dis."},{"key":"74068_CR13","doi-asserted-by":"publisher","unstructured":"Heung, L. J. Innate Immune responses to Cryptococcus. J. Fungi (Basel). 3. https:\/\/doi.org\/10.3390\/jof3030035 (2017).","DOI":"10.3390\/jof3030035"},{"key":"74068_CR14","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1128\/MMBR.00045-10","volume":"75","author":"RS Shapiro","year":"2011","unstructured":"Shapiro, R. S., Robbins, N. & Cowen, L. E. Regulatory circuitry governing fungal development, drug resistance, and disease. Microbiol. Mol. Biol. Rev. 75, 213\u2013267. https:\/\/doi.org\/10.1128\/MMBR.00045-10 (2011).","journal-title":"Microbiol. Mol. Biol. Rev."},{"key":"74068_CR15","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1128\/AAC.01631-10","volume":"55","author":"O Zaragoza","year":"2011","unstructured":"Zaragoza, O. et al. Process analysis of variables for standardization of antifungal susceptibility testing of nonfermentative yeasts. Antimicrob. Agents Chemother. 55, 1563\u20131570. https:\/\/doi.org\/10.1128\/AAC.01631-10 (2011).","journal-title":"Antimicrob. Agents Chemother."},{"key":"74068_CR16","unstructured":"Rex, J. H. et al. M27 A3 Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts; Approved Standard\u2014Third Edition (Clinical and Laboratory Standards Institute, 2008)."},{"key":"74068_CR17","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.jpha.2015.11.005","volume":"6","author":"M Balouiri","year":"2016","unstructured":"Balouiri, M., Sadiki, M. & Ibnsouda, S. K. Methods for in vitro evaluating antimicrobial activity: A review. J. Pharm. Anal. 6, 71\u201379. https:\/\/doi.org\/10.1016\/j.jpha.2015.11.005 (2016).","journal-title":"J. Pharm. Anal."},{"key":"74068_CR18","doi-asserted-by":"publisher","first-page":"1790","DOI":"10.1128\/JCM.42.4.1790-1793.2004","volume":"42","author":"J Chen","year":"2004","unstructured":"Chen, J., Wan, Z. & Li, R. Modified colorimetric assay for susceptibility testing of azole antifungal drugs against Candida species. J. Clin. Microbiol. 42, 1790\u20131793 (2004).","journal-title":"J. Clin. Microbiol."},{"key":"74068_CR19","doi-asserted-by":"publisher","first-page":"2513","DOI":"10.1128\/JCM.39.7.2513-2517.2001","volume":"39","author":"JL Rodriguez-Tudela","year":"2001","unstructured":"Rodriguez-Tudela, J. L., Cuenca-Estrella, M., Diaz-Guerra, T. M. & Mellado, E. Standardization of antifungal susceptibility variables for a semiautomated methodology. J. Clin. Microbiol. 39, 2513\u20132517. https:\/\/doi.org\/10.1128\/JCM.39.7.2513-2517.2001 (2001).","journal-title":"J. Clin. Microbiol."},{"key":"74068_CR20","first-page":"185","volume":"3","author":"SG Nadeem","year":"2013","unstructured":"Nadeem, S. G., Shafiq, A., Hakim, S. T., Anjum, Y. & Kazm, S. U. Effect of Growth Media, pH and temperature on yeast to Hyphal Transition in Candida albicans. J. Clin. Microbiol.3, 185\u2013192 (2013).","journal-title":"J. Clin. Microbiol."},{"key":"74068_CR21","doi-asserted-by":"publisher","unstructured":"Upadhya, R., Lam, W. C., Hole, C. R., Vasselli, J. G. & Lodge, J. K. Cell wall composition in Cryptococcus neoformans is media dependent and alters host response, inducing protective immunity. Front. Fungal Biol. 4https:\/\/doi.org\/10.3389\/ffunb.2023.1183291 (2023).","DOI":"10.3389\/ffunb.2023.1183291"},{"key":"74068_CR22","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1177\/1087057109351311","volume":"15","author":"A K\u00fcmmel","year":"2010","unstructured":"K\u00fcmmel, A. et al. Integration of multiple readouts into the z\u2019 factor for assay quality assessment. J. Biomol. Screen. 15, 95\u2013101. https:\/\/doi.org\/10.1177\/1087057109351311 (2010).","journal-title":"J. Biomol. Screen."},{"key":"74068_CR23","doi-asserted-by":"publisher","unstructured":"Kavanagh, A., Ramu, S., Gong, Y., Cooper, M. A. & Blaskovich, M. A. T. Effects of Microplate Type and Broth Additives on Microdilution MIC susceptibility assays. Antimicrob. Agents Chemother. 63https:\/\/doi.org\/10.1128\/aac.01760-18 (2019).","DOI":"10.1128\/aac.01760-18"},{"key":"74068_CR24","unstructured":"CLSI. Performance standards for Antifungal susceptibility testing of yeasts. 1st ed. CLSI Supplement M60. (2017)."},{"key":"74068_CR25","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1128\/jcm.24.2.269-271.1986","volume":"24","author":"PD Hoeprich","year":"1986","unstructured":"Hoeprich, P. D. & Merry, J. M. Influence of culture medium on susceptibility testing with BAY n 7133 and ketoconazole. J. Clin. Microbiol. 24, 269\u2013271. https:\/\/doi.org\/10.1128\/jcm.24.2.269-271.1986 (1986).","journal-title":"J. Clin. Microbiol."},{"key":"74068_CR26","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.1128\/AAC.34.9.1648","volume":"34","author":"MA Pfaller","year":"1990","unstructured":"Pfaller, M. A. et al. Collaborative investigation of variables in susceptibility testing of yeasts. Antimicrob. Agents Chemother. 34, 1648\u20131654. https:\/\/doi.org\/10.1128\/AAC.34.9.1648 (1990).","journal-title":"Antimicrob. Agents Chemother."},{"key":"74068_CR27","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1038\/s41467-019-13890-z","volume":"11","author":"RB Billmyre","year":"2020","unstructured":"Billmyre, R. B., Clancey, A., Li, S., Doering, L. X., Heitman, J. & T. L. & 5-fluorocytosine resistance is associated with hypermutation and alterations in capsule biosynthesis in Cryptococcus. Nat. Commun. 11, 127. https:\/\/doi.org\/10.1038\/s41467-019-13890-z (2020).","journal-title":"Nat. Commun."},{"key":"74068_CR28","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1111\/j.1574-6968.2010.01972.x","volume":"307","author":"I Nyilasi","year":"2010","unstructured":"Nyilasi, I. et al. In vitro synergistic interactions of the effects of various statins and azoles against some clinically important fungi. FEMS Microbiol. Lett. 307, 175\u2013184. https:\/\/doi.org\/10.1111\/j.1574-6968.2010.01972.x (2010).","journal-title":"FEMS Microbiol. Lett."},{"key":"74068_CR29","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.ijantimicag.2004.11.010","volume":"25","author":"M Mallie","year":"2005","unstructured":"Mallie, M. et al. In vitro susceptibility testing of Candida and Aspergillus spp. to voriconazole and other antifungal agents using Etest: results of a French multicentre study. Int. J. Antimicrob. Agents. 25, 321\u2013328. https:\/\/doi.org\/10.1016\/j.ijantimicag.2004.11.010 (2005).","journal-title":"Int. J. Antimicrob. Agents"},{"key":"74068_CR30","doi-asserted-by":"publisher","first-page":"3254","DOI":"10.1128\/AAC.01750-10","volume":"55","author":"NP Wiederhold","year":"2011","unstructured":"Wiederhold, N. P., Najvar, L. K., Bocanegra, R. A., Kirkpatrick, W. R. & Patterson, T. F. Caspofungin dose escalation for invasive candidiasis due to resistant Candida albicans. Antimicrob. Agents Chemother. 55, 3254\u20133260. https:\/\/doi.org\/10.1128\/AAC.01750-10 (2011).","journal-title":"Antimicrob. Agents Chemother."},{"key":"74068_CR31","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-024-04799-7","author":"A Nussbaumer-Proll","year":"2024","unstructured":"Nussbaumer-Proll, A., Matzneller, P., Eberl, S. & Zeitlinger, M. Pulmonary surfactant impacts in vitro activity of selected antifungal drugs against Candida krusei and Candida albicans. Eur. J. Clin. Microbiol. Infect. Dis. https:\/\/doi.org\/10.1007\/s10096-024-04799-7 (2024).","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"74068_CR32","doi-asserted-by":"publisher","first-page":"4096","DOI":"10.5897\/AJMR2013.5958","volume":"7","author":"S Keerativasee","year":"2013","unstructured":"Keerativasee, S. et al. Heteroresistance to fluconazole among isolates of Cryptococcus neoformans in Northern Thailand. Afr. J. Microbiol. Res. 7, 4096\u20134102. https:\/\/doi.org\/10.5897\/AJMR2013.5958 (2013).","journal-title":"Afr. J. Microbiol. Res."},{"key":"74068_CR33","doi-asserted-by":"publisher","first-page":"5478","DOI":"10.1128\/AAC.02287-12","volume":"57","author":"CE Gast","year":"2013","unstructured":"Gast, C. E., Basso, L. R. Jr., Bruzual, I. & Wong, B. Azole resistance in Cryptococcus gattii from the Pacific Northwest: investigation of the role of ERG11. Antimicrob. Agents Chemother. 57, 5478\u20135485. https:\/\/doi.org\/10.1128\/AAC.02287-12 (2013).","journal-title":"Antimicrob. Agents Chemother."},{"key":"74068_CR34","doi-asserted-by":"publisher","unstructured":"Lu, R. Y. et al. New triazole NT-a9 has potent antifungal efficacy against Cryptococcus neoformans In Vitro and In Vivo. Antimicrob Agents Chemother 64 (2020). https:\/\/doi.org\/10.1128\/AAC.01628-19","DOI":"10.1128\/AAC.01628-19"},{"key":"74068_CR35","first-page":"14401","volume":"10","author":"H Ding","year":"2017","unstructured":"Ding, H. et al. BG40018: a promising drug candidate for the treatment of invasive fungal infections. Int. J. Clin. Exp. Med. 10, 14401\u201314407 (2017).","journal-title":"Int. J. Clin. Exp. Med."},{"key":"74068_CR36","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1534\/genetics.119.302290","volume":"213","author":"KM Pianalto","year":"2019","unstructured":"Pianalto, K. M., Billmyre, R. B., Telzrow, C. L. & Alspaugh, J. A. Roles for stress response and cell Wall Biosynthesis pathways in Caspofungin Tolerance in Cryptococcus neoformans. Genetics. 213, 213\u2013227. https:\/\/doi.org\/10.1534\/genetics.119.302290 (2019).","journal-title":"Genetics"},{"key":"74068_CR37","doi-asserted-by":"publisher","first-page":"114723","DOI":"10.1016\/j.ejmech.2022.114723","volume":"243","author":"Y Xu","year":"2022","unstructured":"Xu, Y. et al. Spiro[benzoxazine-piperidin]-one derivatives as chitin synthase inhibitors and antifungal agents: design, synthesis and biological evaluation. Eur. J. Med. Chem. 243, 114723. https:\/\/doi.org\/10.1016\/j.ejmech.2022.114723 (2022).","journal-title":"Eur. J. Med. Chem."},{"key":"74068_CR38","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/s1413-8670(12)70301-x","volume":"16","author":"M Li","year":"2012","unstructured":"Li, M., Liao, Y., Chen, M., Pan, W. & Weng, L. Antifungal susceptibilities of Cryptococcus species complex isolates from AIDS and non-AIDS patients in Southeast China. Braz J. Infect. Dis. 16, 175\u2013179. https:\/\/doi.org\/10.1016\/s1413-8670(12)70301-x (2012).","journal-title":"Braz J. Infect. Dis."},{"key":"74068_CR39","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1021\/acsinfecdis.5b00044","volume":"1","author":"MA Blaskovich","year":"2015","unstructured":"Blaskovich, M. A., Zuegg, J., Elliott, A. G. & Cooper, M. A. Helping chemists Discover New Antibiotics. ACS Infect. Dis. 1, 285\u2013287. https:\/\/doi.org\/10.1021\/acsinfecdis.5b00044 (2015).","journal-title":"ACS Infect. Dis."},{"key":"74068_CR40","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1021\/acsinfecdis.0c00163","volume":"6","author":"J Zuegg","year":"2020","unstructured":"Zuegg, J., Hansford, K. A., Elliott, A. G., Cooper, M. A. & Blaskovich, M. A. T. How to stimulate and facilitate early stage Antibiotic Discovery. ACS Infect. Dis. 6, 1302\u20131304. https:\/\/doi.org\/10.1021\/acsinfecdis.0c00163 (2020).","journal-title":"ACS Infect. Dis."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-74068-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-74068-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-74068-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,11]],"date-time":"2024-10-11T09:05:59Z","timestamp":1728637559000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-74068-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,8]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["74068"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-74068-2","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4518632\/v1","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,8]]},"assertion":[{"value":"3 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"23407"}}